XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 675,286 $ 647,169
Short-term investments 871,706 819,905
Trade receivables, net 215,015 282,650
Inventory 26,711 27,493
Prepaid expenses and other current assets 52,903 57,530
Total current assets 1,841,621 1,834,747
Long-term investments 551,735 371,112
Property and equipment, net 107,909 104,031
Deferred tax assets, net 116,415 111,663
Goodwill 63,684 63,684
Other long-term assets 280,008 131,002
Total assets 2,961,372 2,616,239
Current liabilities:    
Accounts payable 30,572 24,258
Accrued compensation and benefits 66,927 61,969
Accrued clinical trial liabilities 62,057 77,544
Rebates and fees due to customers 43,791 33,700
Accrued collaboration liabilities 18,277 86,753
Other current liabilities 80,109 53,366
Total current liabilities 301,733 337,590
Long-term portion of deferred revenues 6,491 8,739
Long-term portion of operating lease liabilities 159,838 51,272
Other long-term liabilities 1,908 8,023
Total liabilities 469,970 405,624
Commitments and contingencies
Stockholders' equity    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 322,541 and 318,842 at September 30, 2022, and December 31, 2021, respectively 323 319
Additional paid-in capital 2,512,669 2,427,561
Accumulated other comprehensive loss (17,538) (758)
Accumulated deficit (4,052) (216,507)
Total stockholders' equity 2,491,402 2,210,615
Total liabilities and stockholders' equity $ 2,961,372 $ 2,616,239